Article
Depression-like phenotype following chronic CB1 receptor antagonism.
Neurobiology of disease - 1 Aug 2010
Beyer Chad E, Dwyer Jason M, Piesla Michael J, Platt Brian J, Shen Ru, Rahman Zia, Chan Karen, Manners Melissa T, Samad Tarek A, Kennedy Jeffrey D, Bingham Brendan, Whiteside Garth T
Abstract excerpt
Rimonabant was the first clinically marketed cannabinoid (CB)(1) receptor antagonist developed to treat obesity. Unfortunately, CB(1) receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically, we investigated the effects of rimonabant in rodent models of mood disorders. Chronic treatment with rimonabant increased immobility time in the rat forced swim...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
